Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00566098 · OUTCOME

Disease Response

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma · Source last updated 2023-05-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Percentage of participants with partial or complete response by Bladé criteria. Partial response is defined as a \>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.

Groups in this outcome

MILs in Patients Undergoing an Autologous Peripheral SCT

therapeutic autologous lymphocytes therapeutic tumor infiltrating lymphocytes melphalan autologous hematopoietic stem cell transplantation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MILs in Patients Undergoing an Autologous Peripheral SCT22

Reported measurements

Complete Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MILs in Patients Undergoing an Autologous Peripheral SCT7Not reportedNot reportedNot reportedNot reported
Partial Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MILs in Patients Undergoing an Autologous Peripheral SCT6Not reportedNot reportedNot reportedNot reported
Stable Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MILs in Patients Undergoing an Autologous Peripheral SCT6Not reportedNot reportedNot reportedNot reported
Progressive Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MILs in Patients Undergoing an Autologous Peripheral SCT3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Partial Response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Stable Disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Progressive Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
Percentage of participants with partial or complete response by Bladé criteria. Partial response is defined as a \>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.
groups
  1. description
    therapeutic autologous lymphocytes therapeutic tumor infiltrating lymphocytes melphalan autologous hematopoietic stem cell transplantation
    id
    OG000
    title
    MILs in Patients Undergoing an Autologous Peripheral SCT
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 2 years
title
Disease Response
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice